Biotech and Pharmaceutical Patents at the Federal Circuit: 2012 Year in Review

We invite you to join other members of the local biotech and pharmaceutical industry for breakfast and a seminar discussion with Fish Principal Robert Sullivan, Jr., who will recap several 2012 legal developments in your industries.

Robert will provide their views on several federal court decisions including: Section 101 patent eligibility under Mayo, patentability of human genes under Myriad, the exhaustion doctrine for self-replicating technologies under Bowman, reverse payments in ANDA cases in view of Merck, and more. He will put these cases into context and provide important advice on how they may impact both your prosecution and litigation strategies.